CAR-T cell therapy for inflammatory bowel disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new type of immune cell therapy called CAR-T cells, which target two proteins (CD19 and BCMA) to reduce inflammation in the gut. It is designed for adults with moderate to severe ulcerative colitis or Crohn's disease that has not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have moderate to severe ulcerative colitis or Crohn's disease, confirmed by a doctor with a scope or imaging.
- Your current treatments (like steroids, immunomodulators, or biologics) have stopped working, caused side effects, or are not enough.
- You have had your colitis or Crohn's for at least 3 months, and your disease is active now.
- You have adequate kidney, liver, and blood cell function, as shown by recent lab tests.
- You are willing to stop certain other medications for a period before starting the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Hear when a new Moderate-to-severe Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.